Latest news
Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
Debiopharm and BIOASTER join forces to expand research to combat infectious diseases
Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…
Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale
Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug
GenePOC, a subsidiary of Debiopharm Group, reaches an agreement with Meridian Bioscience for the acquisition of their molecular diagnostics business
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.